This is the case with FXR agonists47, new peroxisome proliferator-activated receptor (PPAR)-gamma or PPAR-alpha modulators48,49, GIP/GLP1 dual agonists50, dual SGLT1/SGLT2 inhibitors51, G protein–coupled receptor (GPCR/GPR) agonists52, apical sodium-dependent bile acid transporter (ASBT) inhibitors53, chemokine receptor 2 and 5 antagonists, fibroblast growth factor 19 agonists54, and modulators of microbiota or their products among many others MetS treatment is an area under intense investigation. This evidence concerns the gene GIP and metabolic syndrome.